carmustine has been researched along with Erythroderma, Sezary in 2 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dummer, R | 1 |
| Foss, F | 1 |
| Dreno, B | 1 |
| Bagot, M | 1 |
| Duvic, M | 1 |
1 review available for carmustine and Erythroderma, Sezary
| Article | Year |
|---|---|
Current treatment of Cutaneous T-Cell Lymphoma.
Topics: Administration, Oral; Administration, Topical; Anticarcinogenic Agents; Apoptosis; Bexarotene; Biops | 2001 |
1 other study available for carmustine and Erythroderma, Sezary
| Article | Year |
|---|---|
Clinical experience: practical management of five patients with cutaneous T-cell lymphoma (CTCL)-related symptoms.
Topics: Aged; Antineoplastic Agents; Carmustine; Combined Modality Therapy; Dermatitis, Exfoliative; Erythem | 2006 |